Rezo Therapeutics is a technology company.
Rezo Therapeutics has raised $78.0M across 1 funding round.
Rezo Therapeutics has raised $78.0M in total across 1 funding round.
Rezo Therapeutics has raised $78.0M in total across 1 funding round.
Rezo Therapeutics's investors include Andreessen Horowitz, Hbm Partners, OrbiMed, Section 32, SR One, Vivo Capital.
Rezo Therapeutics is a San Francisco-based biotechnology company developing precision medicines by mapping disease-related protein networks to identify novel drug targets, primarily in oncology and other serious diseases.[1][2][3] It builds an integrated Sequence to Systems to Drugs (SSD) platform that combines proteomics, genetics, structural biology, chemistry, and bioinformatics with AI to analyze genomic data, uncover tumor-specific targets, and accelerate therapies from discovery to clinical candidates.[1][2][3] The company serves patients with solid tumors and plans to expand into additional areas via partnerships, solving the problem of traditional drug discovery's slowness and silos by targeting overlooked protein-protein interactions.[2][3] Launched in 2022 with $78 million in Series A funding led by SR One, a16z Bio + Health, and Norwest Venture Partners, Rezo shows growth momentum through leadership additions, including CEO Derek Hicks in August 2025 (with 25+ years at Intellia, Spark, and Pfizer) and earlier CEO Nadir Mahmood.[2][3][4]
Rezo Therapeutics emerged from research at the Quantitative Biosciences Institute (QBI) at UCSF, founded by renowned UCSF scientists including co-founder and board chairman George Scangos, Ph.D., who emphasized shifting drug discovery through analysis of protein-protein, genetic, and biochemical interactions.[3] The idea stemmed from integrating unbiased technologies to map "networks that go awry in disease," starting with oncology where mutations rewire cancer-driving pathways.[1][3] Pivotal early traction came with its November 17, 2022 launch and $78 million Series A financing, enabling rapid pipeline advancement in solid tumor oncology with mutation-specific biomarkers.[3] Leadership evolved with Nadir Mahmood, Ph.D., as initial CEO (from Nkarta), succeeded by Derek Hicks in 2025 to drive business development and commercialization.[2][4]
Rezo stands out in biotech through its tech-driven, integrated approach:
Rezo rides the AI-biotech convergence trend, leveraging computational tools to decode complex disease networks amid rising demand for precision oncology amid cancer's global burden.[1][2][3] Timing aligns with post-2022 AI advancements and proteomics/genomics data explosions, favoring network-based discovery over single-target hunts, especially as traditional methods fail "undruggable" interactions.[2][3] Market forces like biomarker-driven trials and VC interest in platform tech (evident in its Series A) propel it, while UCSF origins tap elite talent networks.[3] Rezo influences the ecosystem by pioneering "systems biology" drugging, potentially inspiring collaborations and shifting paradigms from reductionist to holistic models.[3]
Rezo is primed to advance its oncology pipeline toward clinical trials, with new CEO Derek Hicks accelerating partnerships and commercialization.[2] Trends like AI-enhanced multi-omics and allele-specific therapies will shape its path, expanding beyond tumors into immunology or neurodegeneration via alliances.[1][3] Its influence may grow by licensing network maps or SSD tech, redefining biotech efficiency—echoing its launch promise to "unlock a new era of drug discovery" through mapped disease networks.[3][5]
Rezo Therapeutics has raised $78.0M across 1 funding round. Most recently, it raised $78.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $78.0M Series A | Andreessen Horowitz, Hbm Partners, OrbiMed, Section 32, SR One, Vivo Capital |